Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Dysfunction of cholinergic basal forebrain (CBF) neurons of the nucleus basalis (NB) is a cardinal feature of Alzheimer's disease (AD) and correlates with cognitive decline. Survival of CBF neurons depends upon binding of nerve growth factor (NGF) with high‐affinity (trkA) and low‐affinity (p75 NTR) neurotrophin receptors produced within CBF neurons. Since trkA and p75 NTR protein levels are reduced within CBF neurons of people with mild cognitive impairment (MCI) and mild AD, trkA and/or p75 NTR gene expression deficits may drive NB degeneration. Using single cell expression profiling methods coupled with custom‐designed cDNA arrays and validation with real‐time quantitative PCR (qPCR) and in situ hybridization, individual cholinergic NB neurons displayed a significant down regulation of trkA, trkB, and trkC expression during the progression of AD. An intermediate reduction was observed in MCI, with the greatest decrement in mild to moderate AD as compared to controls. Importantly, trk down regulation is associated with cognitive decline measured by the Global Cognitive Score (GCS) and the Mini‐Mental State Examination (MMSE). In contrast, there is a lack of regulation of p75 NTR expression. Thus, trk defects may be a molecular marker for the transition from no cognitive impairment (NCI) to MCI, and from MCI to frank AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545 · cited 1×
“Cholinergic basal forebrain (CBF) neurons of the nucleus basalis (NB) provide the major cholinergic innervation to the cortex and hippocampus, and play a key role in memory and attentional behaviors (Bartus et al. 1982; Mesulam et al. 1983; Baxter and Chiba 1999).”
BackgroundMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627 · cited 2×
“Degeneration of the CBF system suggests that deficits in cortical cholinergic transmission mediated via NB neurons may contribute to the severe cognitive abnormalities seen in advanced AD (Whitehouse et al. 1982; Mufson et al. 2003).”
BackgroundMesulam, M. ‐., Mufson, E. J., Levey, A. I., & Wainer, B. H. (1983) · Journal of Comparative Neurology · doi:10.1002/cne.902140206 · Cited by 1,962
Self-citationNeurotrophin signal transduction in the nervous system
Kaplan, D. R., & Miller, F. D. (2000) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00092-1 · Cited by 1,944
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Nerve Growth Factor Signaling, Neuroprotection, and Neural Repair
Sofroniew, M. V., Howe, C. L., & Mobley, W. C. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1217 · Cited by 1,284
Cited by
Brain-derived neurotrophic factor in neurodegenerative diseases
Zuccato, C., & Cattaneo, E. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.54 · Cited by 947
Alzheimer's Disease: From Pathology to Therapeutic Approaches
Jakob‐Roetne, R., & Jacobsen, H. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802808 · Cited by 626
Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications
Mufson, E. J., Counts, S. E., Perez, S. E., & Ginsberg, S. D. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.11.1703 · Cited by 587
Self-citationThe significance of the cholinergic system in the brain during aging and in Alzheimer’s disease
Schliebs, R., & Arendt, T. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0579-2 · Cited by 530
Neurotrophic factors in Alzheimer’s disease: role of axonal transport
Schindowski, K., Belarbi, K., & Buée, L. (2008) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2007.00378.x · Cited by 335
Jiang, Y., Mullaney, K. A., Peterhoff, C. M., Che, S., Schmidt, S. D., Boyer-Boiteau, A., Ginsberg, S. D., Cataldo, A. M., Mathews, P. M., & Nixon, R. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908953107 · Cited by 292
Self-citationMild cognitive impairment: pathology and mechanisms
Mufson, E. J., Binder, L., Counts, S. E., DeKosky, S. T., deToledo-Morrell, L., Ginsberg, S. D., Ikonomovic, M. D., Perez, S. E., & Scheff, S. W. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0884-1 · Cited by 257
Self-citationGinsberg, S. D., Alldred, M. J., Counts, S. E., Cataldo, A. M., Neve, R. L., Jiang, Y., Wuu, J., Chao, M. V., Mufson, E. J., Nixon, R. A., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.05.030 · Cited by 243
Self-citationZuccato, C., Marullo, M., Conforti, P., MacDonald, M. E., Tartari, M., & Cattaneo, E. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00111.x · Cited by 231
“A number of reports indicate that its expression is dramatically increased under neurodegenerative conditions: for example, increased p75 levels have been found in the basal nucleus of patients with Alzheimer’s disease or temporal lobe epilepsy (19, 37).”
BackgroundThe Neurotrophins and Their Role in Alzheimers Disease
J. Allen, S., J. Watson, J., & Dawbarn, D. (2011) · Current Neuropharmacology · doi:10.2174/157015911798376190 · Cited by 177
“An early significant loss has been reported in the number of TrkA-positive neurons in basal forebrain in MCI (46%) and Alzheimer’s disease (56%) compared to normal [69], and this reduction is associated with cognitive decline [70, 71].”
BackgroundBasal forebrain cholinergic signalling: development, connectivity and roles in cognition
Ananth, M. R., Rajebhosale, P., Kim, R., Talmage, D. A., & Role, L. W. (2023) · Nature Reviews Neuroscience · doi:10.1038/s41583-023-00677-x · Cited by 148
Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome
Hamlett, E. D., Goetzl, E. J., Ledreux, A., Vasilevko, V., Boger, H. A., LaRosa, A., Clark, D., Carroll, S. L., Carmona‐Iragui, M., Fortea, J., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.012 · Cited by 129
“Dysregulation of alternative splicing of tau has been reported in DS and in AD [37] and may also underlie the abnormal hyperphosphorylation of tau [38].”
BackgroundSelf-citationChoi, J. H. K., Berger, J. D., Mazzella, M. J., Morales‐Corraliza, J., Cataldo, A. M., Nixon, R. A., Ginsberg, S. D., Levy, E., & Mathews, P. M. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06277.x · Cited by 83
“…brain at 5 months of age Hemibrains lacking cerebellum from 5-month-old (n = 4 Ts65Dn, n = 4 2N) and 12-month-old (n = 4 Ts65Dn, n = 4 2N) Ts65Dn mice and 2N littermate controls were analyzed via real-time qPCR using a Taqman assay (Ginsberg 2005; Ginsberg and Mirnics 2006; Ginsberg et al. 2006).”
MethodSelf-citationPlasma BDNF levels vary in relation to body weight in females
Pillai, A., Bruno, D., Sarreal, A. S., Hernando, R. T., Saint-Louis, L. A., Nierenberg, J., Ginsberg, S. D., Pomara, N., Mehta, P. D., Zetterberg, H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039358 · Cited by 82
“There is mounting evidence that TrkB is downregulated in specific brain regions (including CA1 pyramidal neurons and cholinergic basal forebrain neurons) in mild cognitive impairment [55–56] and peripheral ganglia during the normal aging process [57–58].”
BackgroundSelf-citationXiang, J., Wang, Z.-H., Ahn, E. H., Liu, X., Yu, S.-P., Manfredsson, F. P., Sandoval, I. M., Ju, G., Wu, S., & Ye, K. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901348116 · Cited by 67
Eggert, S., Kins, S., Endres, K., & Brigadski, T. (2022) · Biological Chemistry · doi:10.1515/hsz-2021-0330 · Cited by 46
“Gene expression of full length TrkB inversely correlated with antemortem cognitive assessment measures as well as diffuse A β plaques in the entorhinal cortex (Ginsberg et al. 2006, 2019a).”
BackgroundUltrasound delivery of a TrkA agonist confers neuroprotection to Alzheimer-associated pathologies
Xhima, K., Markham-Coultes, K., Hahn Kofoed, R., Saragovi, H. U., Hynynen, K., & Aubert, I. (2022) · Brain · doi:10.1093/brain/awab460 · Cited by 43
Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer’s disease
Salasova, A., Monti, G., Andersen, O. M., & Nykjaer, A. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00576-2 · Cited by 42
Sanphui, P., Pramanik, S. K., Chatterjee, N., Moorthi, P., Banerji, B., & Biswas, S. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078842 · Cited by 38
“TrkA, the receptor for NGF also shown to be reduced in early-stage AD and this decline is associated with cognitive decline [21].”
BackgroundMethodOnyango, I. G., Ahn, J., Tuttle, J. B., Bennett Jr, J. P., & Swerdlow, R. H. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06871.x · Cited by 25
“…in Ab is associated with the down-regulation of the high affinity neurotrophin receptor tropomyocin receptor kinase (TrkA) and an up-regulation or at least maintenance of the common low affinity p75 neurotrophin receptor (p75NTR) (Mufson and Kordower 1997; Ginsberg et al. 2006; Haines 2006).”
BackgroundLi, H., Initiative, F. T. A. D. N., Liu, H., Lutz, M. W., & Luo, S. (2023) · Journal of Alzheimer's Disease · doi:10.3233/jad-220680 · Cited by 17
“Certain neurotrophins exert their effect on cellular signaling by interacting with Trk tyrosine kinase receptors, and a previous study has indicated that the Trk defects might be a marker for the conversion from MCI to AD [21, 22].”
Metadata
- Authors
- Ginsberg, S. D., Che, S., Wuu, J., Counts, S. E., & Mufson, E. J.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2006-03-15
- Volume
- 97
- Issue
- 2
- Pages
- 475-487
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1494415215
- Cited by
- 255
- References
- 65
- FWCI
- 9.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.